TrialPath

Find a study

Match me to a study

93 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

89 studies on the map

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — University of Alabama at Birmingham, BirminghamA Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease — Banner Sun Health Research Institute, Sun CityA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamA Study of Buntanetap in Participants With PD — University of Alabama at Birmingham, BirminghamA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockPimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis — Southern Arizona VA Health Care System, Tucson, AZ, TucsonThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease — Barrow Neurological Institute, PhoenixA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamA Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease — Site-049, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamA Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease — Collaborative Neuroscience Network - CNS, Los AlamitosStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkSAD Study in Patients With Parkinson's Disease and Motor Fluctuations — Rocky Mountain Clinical Research, EnglewoodSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaA Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease — University of Kentucky Medical Center, LexingtonA Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease — Austin Clinic PPD, AustinArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntoniorTMS to Improve Cognition in Parkinson's — Jesse Brown VA Medical Center, Chicago, IL, ChicagoCortical Electrophysiology of Response Inhibition in Parkinson's Disease — Emory University Hospital, AtlantaThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, Richmond[18F]F-DOPA Imaging in Patients With Autonomic Failure — Vanderbilt University Medical Center, NashvillePET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease — National Institutes of Health Clinical Center, BethesdaPhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborVirtual tES Device Treatment for Parkinson's Disease Motor Symptoms — U LLC Headquarters, ClevelandA Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery — University of Kentucky, LexingtonA Pilot Study of In-lab Dynamic Standing in Parkinson's Disease — Domino's Farms, Ann ArborThis Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. — Cornell University Weill Medical College, New YorkAutologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies — University of Kentucky, LexingtonTransplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) — University of California, San Diego, La JollaBOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease — Cleveland Clinic, ClevelandCharacterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases — Vanderbilt University Medical Center, NashvilleEnrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. — UPMC Presbyterian Hospital, PittsburghUsing taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease — Wellness, Health and Research Facility at UAB, BirminghamFirst-in-Human Single and Multiple Dose of HL-400 — Pharmaron CPC, Inc., BaltimoreThe University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy — UAB Advanced Imaging Facility, BirminghamTreating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons — Massachusetts General Hospital, BostonA Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's — Northwestern University, EvanstonPersonalized Real-Time DBS and PD Mechanisms — Cleveland Clinic, ClevelandEffects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure — Autonomic Dysfunction Center/ Vanderbilt University Medical Center, NashvilleEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East WindsorDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis — Lurie Children's Hospital/Northwestern University, ChicagoPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborMolecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San Francisco